The international study Skyline plans to enroll 1.200 participants worldwide to assess a new treatment against Alzheimer's disease.
The thesis develved into urrent knowledge of the disease during its preclinical stage and provides new evidence for its early detection.
Currently, the BBRC researcher collaborates with ISGlobal in the NCDs (Non-Communicable Diseases) and Environment program on the effects of the pandemic on mental health.
The pharmaceutical representatives have had a chance to see first-hand the new equipment of the Pasqual Maragall Foundation’s research center
Lumbar puncture is a procedure to extract cerebrospinal fluid that allows the study of biomarkers of Alzheimer's disease.
From our commitment to transparency, we present the strategic axes and future lines of the Pasqual Maragall Foundation to our participants in studies, partners, collaborators and civil society
On the occasion of the AD / PD 2022 congress, held in Barcelona, the BBRC hosted researchers from all over the world. At the meeting there was a presentation by Prof. Henrik Zetterberg of the University of Gothenburg
This is the AHEAD clinical trial, an international multicenter study to evaluate the efficacy and safety of lecanemab
AD / PD 2022, held this year in Barcelona, presents work carried out at the Pasqual Maragall Foundation’s research center, in three oral presentations and a poster. In addition, one of our researchers will moderate a symposium of the congress